A

August Bioservices

US-based CDMO for end-to-end drug development

Overview

August Bioservices is a US-based CDMO that provides end-to-end drug development and manufacturing from preclinical to commercial stages. It manages all steps in a single program, including research, development, testing, laboratory services, and sterile fill/finish, while following cGMP standards. It differentiates itself with a hybrid model that combines large-CDMO scale and capabilities with a strong focus on customer service and integrated workflows. Its goal is to help clients bring safe and effective drugs to market efficiently by delivering comprehensive development and manufacturing under one roof.

Work here?Claim your company

About August Bioservices

Simplify's Rating
Why August Bioservices is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Industrial & ManufacturingHealthcare

Company Size

51-200

Company Stage

Series B

Total Funding

$88.6M

Headquarters

Nashville, TN

Founded

2017

Get referred to August Bioservices

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Vial filling qualified in July 2026, unlocking throughput from the $60 million expansion.
  • Series B funding in 2025 financed an additional high-speed vial suite and automation.
  • August Bioservices' 2026 event calendar signals active business development across BIO, CPHI, and Contract Pharma.

What critics are saying

  • Sterile injectable capacity takes roughly 30 months to qualify, delaying revenue from expansion.
  • A single FDA contamination finding can halt lines, erase customer trust, and trigger recalls.
  • Specialization in sterile injectables concentrates exposure if outsourcing demand shifts or major clients leave.

What makes August Bioservices unique

  • Nashville campus offers sterile injectables, development, and manufacturing on one contiguous site.
  • August Bio runs fully isolated vial, syringe, and IV bag lines with in-house analytics.
  • The 2026 site integrates automated inspection, labeling, packaging, and serialization for faster releases.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$88.6M

Above

Industry Average

Funded Over

2 Rounds

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.
Series B Funding Comparison
Above Average

Industry standards

$35M
$45M
$65M
$65M
$100M

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

1%

1 year growth

3%

2 year growth

0%
Business Wire
Sep 16th, 2026
August Bioservices Closes $23.6 Million Series A Extension to Expand U.S. Biopharma Manufacturing Capabilities

August Bioservices,LLC, a contract development and manufacturing organization (CDMO) providing drug discovery, development, and pharmaceutical manufacturing ...

Pattern of USA
Sep 10th, 2026
Impact of August Biopharmaceutical Layoffs: Over 500 Jobs Lost, Marking a 90% Decrease Compared to the Previous Year

Impact of August Biopharmaceutical Layoffs: Over 500 Jobs Lost, Marking a 90% Decrease Compared to the Previous Year 09/10/2026

The Healthcare Technology Report
Mar 18th, 2026
Jenn Adams named Healthcare Technology CEO of the Year.

Jenn Adams named Healthcare Technology CEO of the Year. Published. March 18, 2026 At this year's NYC Awards Night, The Healthcare Technology Repo had the privilege of recognizing several exceptional leaders advancing innovation across healthcare technology. Congratulations to Jenn Adams, CEO of August Bioservices, on being named Healthcare Technology CEO of the Year. Jenn has led August Bioservices since its founding in 2020, building a contract development and manufacturing organization (CDMO) dedicated to sterile injectable therapies. Headquartered in Nashville, the company provides development and manufacturing services that help drug developers advance innovative therapies from early development through commercialization. Accepting the award, Jenn shared: "When we started our company five and a half years ago, we had a really clear goal and we set out to build a CDMO focused on sterile injectables that could truly serve as a partner to our clients, providing deep technical expertise and a state-of-the-art facility and equipment - all designed to help advance innovative therapies through development and commercialization. Our aspiration is to show up so fully for our clients that they cannot tell the difference anymore. It's indistinguishable to them who is on their team and who is on our team because we're working shoulder to shoulder to make sure the drug is advanced. And then we're bridging the innovation and bringing it to patients who need that innovation in the form of therapies." Please join The Healthcare Technology Repo in congratulating Jenn Adams on this well-deserved recognition. Picture: Jenn Adams speaks at NYC Awards Night

Teknovation.biz
Dec 13th, 2024
Tennessee Emerges As A Leading State For Bioscience R&D

A new report from the Biotechnology Innovation Organization (BIO) and TEConomy Partners LLC finds Tennessee has emerged as a leading state for bioscience research and development, with bioscience RD accounting... The post Tennessee emerges as a leading state for bioscience RD appeared first on Teknovation.biz.

Teknovation.biz
Jun 30th, 2024
News & Notes | Ut Research Foundation Welcomes Four Interns

Like this story? Please share!News & Notes | UT Research Foundation welcomes four interns ETSU's Innovation Lab Director Dr. Audrey Depelteau served as a judge at last week's 2024 SelectUSA Investment Summit.From Knoxville:To promote the commercialization of University of Tennessee (UT) innovations and to help train the next generation of commercialization professionals, the UT Research Foundation (UTRF) recently welcomed three new interns and one returning intern across its Knoxville and Memphis offices.In Knoxville, Andrea Gutierrez-Cortez and Lauren Williams , rising second-year law students at UT, Knoxville (UTK), joined the team as Commercialization Analysts. Jacob Hale is returning for his second year with UTRF as a Senior Commercialization Analyst. Hale is a rising third-year law student, while Gutierrez-Cortez completed her bachelor’s degree in human biology at the University of California, San Diego, and Williams majored in biomedical engineering at UTK.and , rising second-year law students at UT, Knoxville (UTK), joined the team as Commercialization Analysts. is returning for his second year with UTRF as a Senior Commercialization Analyst. Hale is a rising third-year law student, while Gutierrez-Cortez completed her bachelor’s degree in human biology at the University of California, San Diego, and Williams majored in biomedical engineering at UTK

Recently Posted Jobs

Sign up to get curated job recommendations

August Bioservices is Hiring for 25 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs